{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T21:53:33Z","timestamp":1773698013210,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.yexcr.2021.112504","type":"journal-article","created":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T09:30:50Z","timestamp":1611739850000},"page":"112504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["The NRG3\/ERBB4 signaling cascade as a novel therapeutic target for canine glioma"],"prefix":"10.1016","volume":"400","author":[{"given":"Shunsuke","family":"Noguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomotsugu","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6942-9919","authenticated-orcid":false,"given":"Kazuhiko","family":"Kurozumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Nakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Akiyoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Kamishina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexcr.2021.112504_bib1","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/jvim.12136","article-title":"Postmortem evaluation of 435 cases of intracranial neoplasia in dogs and relationship of neoplasm with breed, age, and body weight","volume":"27","author":"Song","year":"2013","journal-title":"J. Vet. Intern. Med."},{"key":"10.1016\/j.yexcr.2021.112504_bib2","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noaa215.388","article-title":"Phase I trial of convection-enhanced delivery of IL13RA2 and EPHA2 receptor targeted cytotoxins in dogs with spontaneous intracranial gliomas","author":"Rossmeisl","year":"2020","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.yexcr.2021.112504_bib3","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ccell.2020.01.004","article-title":"Comparative molecular Life history of spontaneous canine and human gliomas","volume":"37","author":"Amin","year":"2020","journal-title":"Canc. Cell"},{"key":"10.1016\/j.yexcr.2021.112504_bib4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/07357907.2018.1514622","article-title":"Naturally occurring canine glioma as a model for novel therapeutics","volume":"36","author":"Hubbard","year":"2018","journal-title":"Canc. Invest."},{"key":"10.1016\/j.yexcr.2021.112504_bib5","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/vco.12316","article-title":"Frameless stereotactic radiotherapy alone and combined with temozolomide for presumed canine gliomas","volume":"16","author":"Dolera","year":"2018","journal-title":"Vet. Comp. Oncol."},{"key":"10.1016\/j.yexcr.2021.112504_bib6","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/vco.12401","article-title":"Survival times in dogs with presumptive intracranial gliomas treated with oral lomustine: a comparative retrospective study (2008-2017)","volume":"16","author":"Moirano","year":"2018","journal-title":"Vet. Comp. Oncol."},{"key":"10.1016\/j.yexcr.2021.112504_bib7","first-page":"113","article-title":"MicroRNAs as tumour suppressors in canine and human melanoma cells and as a prognostic factor in canine melanomas","volume":"11","author":"Noguchi","year":"2013","journal-title":"Vet. Comp. Oncol."},{"key":"10.1016\/j.yexcr.2021.112504_bib8","doi-asserted-by":"crossref","first-page":"E1611","DOI":"10.3390\/ijms20071611","article-title":"The roles of MicroRNA in lung cancer. LID - E1611 [pii] LID - 10.3390\/ijms20071611 [doi]","volume":"20","author":"Wu","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yexcr.2021.112504_bib9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10072-016-2710-y","article-title":"The expression of miRNA-221 and miRNA-222 in gliomas patients and their prognosis","volume":"38","author":"Xue","year":"2017","journal-title":"Neurol. Sci."},{"issue":"5 Pt A","key":"10.1016\/j.yexcr.2021.112504_bib10","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.bbadis.2018.02.022","article-title":"PVT1 regulates the malignant behaviors of human glioma cells by targeting miR-190a-5p and miR-488-3p","volume":"1864","author":"Xue","year":"2018","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"key":"10.1016\/j.yexcr.2021.112504_bib11","first-page":"2151","article-title":"miR2963p promotes the proliferation of glioblastoma cells by targeting ICAT","volume":"21","author":"Zhou","year":"2020","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.yexcr.2021.112504_bib12","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/cne.24762","article-title":"Neuregulin and ErbB expression is regulated by development and sensory experience in mouse visual cortex","volume":"528","author":"Grieco","year":"2020","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.yexcr.2021.112504_bib13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/annonc\/mdm431","article-title":"ErbB\/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis","volume":"19","author":"Revillion","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.yexcr.2021.112504_bib14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.yexcr.2021.112504_bib15","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.tips.2019.10.004","article-title":"A third shot at EGFR: new opportunities in cancer therapy","volume":"40","author":"Guardiola","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.yexcr.2021.112504_bib16","doi-asserted-by":"crossref","first-page":"101965","DOI":"10.1016\/j.ctrv.2020.101965","article-title":"HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis","volume":"84","author":"Schettini","year":"2020","journal-title":"Canc. Treat Rev."},{"key":"10.1016\/j.yexcr.2021.112504_bib17","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/ijd.12961","article-title":"Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies","volume":"55","author":"Rudnick","year":"2016","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.yexcr.2021.112504_bib18","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.3389\/fonc.2019.01308","article-title":"Epidermal growth factor receptor family and its role in gastric cancer","volume":"9","author":"Arienti","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.yexcr.2021.112504_bib19","first-page":"1459","article-title":"Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor","volume":"7","author":"Ciardiello","year":"2001","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.yexcr.2021.112504_bib20","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1200\/JCO.2005.16.584","article-title":"Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas","volume":"23","author":"Burris","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexcr.2021.112504_bib21","first-page":"2271","article-title":"Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer","volume":"31","author":"Bouche","year":"2011","journal-title":"Antcancer Res"},{"key":"10.1016\/j.yexcr.2021.112504_bib22","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.wneu.2011.09.005","article-title":"Novel animal glioma models that separately exhibit two different invasive and angiogenic phenotypes of human glioblastomas","volume":"78","author":"Inoue","year":"2012","journal-title":"World Neurosurg"},{"key":"10.1016\/j.yexcr.2021.112504_bib23","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.canlet.2011.04.005","article-title":"MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells","volume":"307","author":"Noguchi","year":"2011","journal-title":"Canc. Lett."},{"key":"10.1016\/j.yexcr.2021.112504_bib24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ctrv.2006.01.003","article-title":"Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours","volume":"32","author":"Halatsch","year":"2006","journal-title":"Canc. Treat Rev."},{"key":"10.1016\/j.yexcr.2021.112504_bib25","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3109\/07357907.2011.630050","article-title":"Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets","volume":"30","author":"Mao","year":"2012","journal-title":"Canc. Invest."},{"key":"10.1016\/j.yexcr.2021.112504_bib26","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/neuonc\/nov319","article-title":"Epidermal growth factor receptor targeting and challenges in glioblastoma","volume":"18","author":"Thorne","year":"2016","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.yexcr.2021.112504_bib27","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.yexcr.2011.03.015","article-title":"Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines","volume":"317","author":"Carrasco-Garc\u00eda","year":"2011","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.yexcr.2021.112504_bib28","doi-asserted-by":"crossref","first-page":"33867","DOI":"10.18632\/oncotarget.5293","article-title":"EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cells","volume":"6","author":"Struve","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.yexcr.2021.112504_bib29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/glia.20197","article-title":"Neuregulin-1 enhances survival of human astrocytic glioma cells","volume":"51","author":"Ritch","year":"2005","journal-title":"Glia"},{"key":"10.1016\/j.yexcr.2021.112504_bib30","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s13046-019-1264-2","article-title":"Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells","volume":"38","author":"Vengoji","year":"2019","journal-title":"J. Exp. Clin. Canc. Res."},{"key":"10.1016\/j.yexcr.2021.112504_bib31","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrn2392","article-title":"Neuregulin 1 in neural development, synaptic plasticity and schizophrenia","volume":"9","author":"Mei","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.yexcr.2021.112504_bib32","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/(SICI)1096-9896(199807)185:3<236::AID-PATH118>3.0.CO;2-7","article-title":"Expression of the c-erbB-4\/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types","volume":"185","author":"Srinivasan","year":"1998","journal-title":"J. Pathol."},{"key":"10.1016\/j.yexcr.2021.112504_bib33","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2018.11.014","article-title":"Small molecule inhibitors targeting the EGFR\/ErbB family of protein-tyrosine kinases in human cancers","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482721000355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482721000355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T04:35:32Z","timestamp":1757997332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014482721000355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0014482721000355"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2021.112504","relation":{},"ISSN":["0014-4827"],"issn-type":[{"value":"0014-4827","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The NRG3\/ERBB4 signaling cascade as a novel therapeutic target for canine glioma","name":"articletitle","label":"Article Title"},{"value":"Experimental Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexcr.2021.112504","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112504"}}